Technical Data
Complement C1q, Human
C1q is serum glycoprotein of 18-polypeptides chains consisting of three non-identical subunits, A (29kD), B (26kD) and C (246aa, 19kD) in molar ratio of 1:2:2. C1Q in the plasma is complexed with two proenzymes C1r and two C1s molecules to form the first component of complement (C1). Activation of complement via classical pathway is triggered by binding of globular head of C1q to immune complexes containing IgG (Fc-region) or IgM or to a variety of other activating substances, including C-reactive protein, retrovirus and mitochondria. Subsequent to C1q binding, c1r and C1s are converted to proteolytic enzymes that are responsible to continuation of activation via the classical pathway. Normal plasma concentration of C1q is 100-180mg/L.

Suitable for use in ELISA, RID, Double Diffusion, IEP and Rocket IEP. Other applications not tested.

Recommended Dilution:
RID: Neat-1:2 using 0.1ul antiserum/cm2 in gel vs 20ul fresh plasma.
Double Diffusion: 10ul antiserum vs 20ul fresh plasma
Note: The use of 3% PEG 6000 with 1.4% agarose in a suitable buffer such as Tris/Glycine/EDTA (6.1g/L Tris, 3.8g/L Glycine, 8.8g/L NaCl, 3.7g/L EDTA (pH 8.4)) is recommended.
Note: Results can be enhanced by washing completed agarose gels in saline, drying and finally staining with a protein stain such as coomassie blue.
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
1ml-20°CBlue IceHumanSheep
Human C1q purified from plasma.
Supplied as a liquid in GBS, pH 7.4, 0.099% sodium azide, 0.1% EACA, 0.01% benzamidine, 1mM EDTA.
Recognizes human Complement C1q. Single arc when tested by IEP against fresh human plasma. Identity has been confirmed by double diffusion (Ouchterlony) against fresh human plasma and a known anti-human C1q.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Hinton, P.R., et al., (2006), “An Engineered Human IgG1 Antibody with Longer Serum Half-Life,” Journal of Immunology, 176:346-356. 2. Idusogie, Esohe E., et al., (2000), “Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc”, The Journal of Immunology, 164: 4178-4184.